Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7EMN

The atomic structure of SHP2 E76A mutant

Replaces:  6IHZ
Summary for 7EMN
Entry DOI10.2210/pdb7emn/pdb
DescriptorTyrosine-protein phosphatase non-receptor type 11 (2 entities in total)
Functional Keywordsphosphatase, hydrolase
Biological sourceHomo sapiens (Human)
Total number of polymer chains2
Total formula weight122780.52
Authors
Luo, F.,Xie, J.J.,Zhu, J.D.,Liu, C. (deposition date: 2021-04-14, release date: 2021-05-05, Last modification date: 2023-11-29)
Primary citationTao, Y.,Xie, J.,Zhong, Q.,Wang, Y.,Zhang, S.,Luo, F.,Wen, F.,Xie, J.,Zhao, J.,Sun, X.,Long, H.,Ma, J.,Zhang, Q.,Long, J.,Fang, X.,Lu, Y.,Li, D.,Li, M.,Zhu, J.,Sun, B.,Li, G.,Diao, J.,Liu, C.
A novel partially open state of SHP2 points to a "multiple gear" regulation mechanism.
J.Biol.Chem., 296:100538-100538, 2021
Cited by
PubMed Abstract: The protein tyrosine phosphatase SHP2 mediates multiple signal transductions in various cellular pathways, controlled by a variety of upstream inputs. SHP2 dysregulation is causative of different types of cancers and developmental disorders, making it a promising drug target. However, how SHP2 is modulated by its different regulators remains largely unknown. Here, we use single-molecule fluorescence resonance energy transfer and molecular dynamics simulations to investigate this question. We identify a partially open, semiactive conformation of SHP2 that is intermediate between the known open and closed states. We further demonstrate a "multiple gear" regulatory mechanism, in which different activators (e.g., insulin receptor substrate-1 and CagA), oncogenic mutations (e.g., E76A), and allosteric inhibitors (e.g., SHP099) can shift the equilibrium of the three conformational states and regulate SHP2 activity to different levels. Our work reveals the essential role of the intermediate state in fine-tuning the activity of SHP2, which may provide new opportunities for drug development for relevant cancers.
PubMed: 33722610
DOI: 10.1016/j.jbc.2021.100538
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3 Å)
Structure validation

246905

PDB entries from 2025-12-31

PDB statisticsPDBj update infoContact PDBjnumon